| III-69 Shayne Watson Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies Thursday 09:55-11:20 |
| III-69 Shayne Watson Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies Thursday 09:55-11:20 |